Lung-RADS · Tórax
Sistemas/Tórax

Lung-RADS Lung CT Screening Reporting and Data System

vigente

Structured assessment categories and management for low dose CT lung cancer screening.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.
Escala de categorias
01234A4B4XS

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor
American College of Radiology
Versão
v2022
Ano
2022
Família
léxico
Tipo de lógica
flat
Modalidade
CT
Fonte primária
Lung CT Screening Reporting and Data System (Lung-RADS) version 2022
Última verificação
2026-07-24
Última checagem
2026-08-12

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Use in screening only. Follow the cited outcome for management; category timing is measured from the exam currently being interpreted.

Mostrar a lógica estruturada (JSON)
{
  "applicability": {
    "use_for": "Lung cancer screening CT examinations.",
    "exclude": [
      "incidental_nodule_outside_screening",
      "post_diagnosis_lung_cancer_staging"
    ],
    "incidental_alternative": "fleischner-2017"
  },
  "categories": [
    "0",
    "1",
    "2",
    "3",
    "4A",
    "4B",
    "4X",
    "S"
  ],
  "exam_rule": "Assign one numeric category from 0-4X according to the finding with the highest suspicion; S is an optional modifier, not a replacement category.",
  "measurement": {
    "mean_diameter": "Average long and short axes in any plane, report to 0.1 mm.",
    "volume_rounding": "nearest whole mm3",
    "growth": ">1.5 mm increase in mean diameter within 12 months",
    "threshold_crossing": "Reclassify when a nodule crosses a category size threshold even if it does not meet the growth definition."
  },
  "nodule_rules": {
    "solid": [
      {
        "outcome_code": "2",
        "when": [
          "baseline <6 mm",
          "new <4 mm"
        ]
      },
      {
        "outcome_code": "3",
        "when": [
          "baseline 6 to <8 mm",
          "new 4 to <6 mm"
        ]
      },
      {
        "outcome_code": "4A",
        "when": [
          "baseline 8 to <15 mm",
          "growing <8 mm",
          "new 6 to <8 mm"
        ]
      },
      {
        "outcome_code": "4B",
        "when": [
          "baseline >=15 mm",
          "new or growing >=8 mm",
          "slow growth over multiple exams without >1.5 mm growth in any 12-month interval"
        ]
      }
    ],
    "part_solid": [
      {
        "outcome_code": "2",
        "when": [
          "baseline total mean diameter <6 mm"
        ]
      },
      {
        "outcome_code": "3",
        "when": [
          "baseline total >=6 mm and solid component <6 mm",
          "new total <6 mm"
        ]
      },
      {
        "outcome_code": "4A",
        "when": [
          "baseline total >=6 mm and solid component 6 to <8 mm",
          "new or growing solid component <4 mm"
        ]
      },
      {
        "outcome_code": "4B",
        "when": [
          "baseline solid component >=8 mm",
          "new or growing solid component >=4 mm",
          "slow growth over multiple exams without >1.5 mm growth in any 12-month interval"
        ]
      }
    ],
    "ground_glass": [
      {
        "outcome_code": "2",
        "when": [
          "baseline, new, or growing <30 mm",
          ">=30 mm and stable or slowly growing"
        ]
      },
      {
        "outcome_code": "3",
        "when": [
          "baseline or new >=30 mm"
        ]
      },
      {
        "outcome_code": "4X",
        "when": [
          "doubles in size within 1 year or has another additional suspicious feature"
        ]
      }
    ],
    "juxtapleural": [
      {
        "outcome_code": "2",
        "when": [
          "<10 mm mean diameter",
          "smooth margins",
          "oval, lentiform, or triangular morphology"
        ]
      }
    ],
    "airway": [
      {
        "outcome_code": "2",
        "when": [
          "subsegmental",
          "segmental or proximal with internal air and no soft-tissue nodule"
        ]
      },
      {
        "outcome_code": "4A",
        "when": [
          "segmental or more proximal at baseline"
        ]
      },
      {
        "outcome_code": "4B",
        "when": [
          "segmental or more proximal and persistent at 3-month CT"
        ]
      }
    ],
    "atypical_pulmonary_cyst": [
      {
        "outcome_code": "3",
        "when": [
          "thick-walled cyst with growing cystic component"
        ]
      },
      {
        "outcome_code": "4A",
        "when": [
          "thick-walled cyst at baseline",
          "multilocular cyst at baseline",
          "cyst becomes multilocular"
        ]
      },
      {
        "outcome_code": "4B",
        "when": [
          "thick-walled cyst with increasing wall thickness or nodularity",
          "multilocular cyst with increased loculation or new/increasing opacity"
        ]
      }
    ]
  },
  "non_nodule_rules": [
    {
      "outcome_code": "0",
      "when": "prior CT is being obtained, lungs are incompletely evaluated, or indeterminate infection/inflammation warrants 1-3 month LDCT"
    },
    {
      "outcome_code": "1",
      "when": "no nodules or only nodules with definitely benign calcification/fat"
    },
    {
      "outcome_code": "4X",
      "when": "a category 3 or 4 nodule has added suspicious findings such as spiculation, lymphadenopathy, or metastatic disease"
    }
  ],
  "stepped_management": [
    {
      "from": "3",
      "if": "stable or decreased at 6-month LDCT",
      "to": "2",
      "next": "12-month screening LDCT from the current exam"
    },
    {
      "from": "4A",
      "if": "stable or decreased at 3-month LDCT",
      "to": "3",
      "next": "6-month LDCT from the current exam"
    },
    {
      "from": "3_after_4A",
      "if": "stable or decreased at the next 6-month LDCT",
      "to": "2",
      "next": "12-month screening LDCT from the current exam"
    }
  ],
  "modifier": {
    "outcome_code": "S",
    "apply_when": "clinically significant or potentially significant non-lung-cancer finding that is new or unexpectedly changing",
    "do_not_repeat_when": "the finding is already known and has been or is being evaluated"
  },
  "source_locator": "ACR Lung-RADS v2022 Assessment Categories table and Notes 1-16; v2022 Summary of Changes, stepped management section."
}

Categorias num relance

Cat.SignificadoCondutaRiscoFonte
0
Incomplete
Incomplete: a prior chest CT is being located for comparison, part or all of the lungs cannot be evaluated, or findings suggest an inflammatory/infectious process.
Obtain comparison with prior chest CT and/or additional lung-cancer-screening CT; for suspected infection/inflammation, 1-3 month LDCT.Published estimated population prevalence ~1% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 0 row
1
Negative
Negative: no lung nodules, or nodules with definitely benign features (complete/central/popcorn/concentric-ring calcification, or fat-containing).
Continue annual screening with 12-month LDCT.Published estimated population prevalence 39% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 1 row
2
Benign appearance or behavior
Benign by imaging features or indolent behavior. Includes: juxtapleural nodule under 10 mm with benign morphology; solid nodule under 6 mm at baseline or new under 4 mm; part-solid nodule with total mean diameter under 6 mm at baseline; non-solid (ground-glass) nodule under 30 mm at baseline/new/growing, or >=30 mm if stable/slowly growing; subsegmental airway nodule.
Continue annual screening with 12-month LDCT.Published estimated population prevalence 45% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 2 row
3
Probably benign
Probably benign. Includes: solid nodule 6 to under 8 mm at baseline (or new 4 to under 6 mm); part-solid nodule with total mean diameter >=6 mm and solid component under 6 mm at baseline (or new under 6 mm total); non-solid (ground-glass) nodule >=30 mm at baseline or new; thick-walled atypical cyst with a growing cystic component.
Short-interval follow-up with 6-month LDCT. If stable or decreased at that exam, reclassify as Lung-RADS 2 and obtain the next screening LDCT 12 months from the current exam.Published estimated population prevalence 9% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 3 row
4A
Suspicious
Suspicious. Includes: solid nodule 8 to under 15 mm at baseline (or growing under 8 mm, or new 6 to under 8 mm); part-solid nodule with total mean diameter >=6 mm and solid component 6 to under 8 mm at baseline (or new/growing solid component under 4 mm); segmental or more proximal airway nodule at baseline; certain atypical pulmonary cysts (thick-walled, or multilocular at baseline, or one becoming multilocular).
3-month LDCT; PET/CT may be considered when there is a solid nodule or solid component of 8 mm or larger. If stable or decreased at 3 months, reclassify as Lung-RADS 3 and obtain 6-month LDCT from that current exam; if again stable or decreased, step down to category 2 with 12-month LDCT from the latest exam.Published estimated population prevalence 4% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 4A row
4B
Very suspicious
Very suspicious. Includes: solid nodule >=15 mm at baseline (or new/growing >=8 mm); part-solid nodule with solid component >=8 mm at baseline (or new/growing solid component >=4 mm); certain growing/atypical cysts; slow-growing solid or part-solid nodule that demonstrates growth over multiple screening exams; segmental or more proximal airway nodule that is stable or growing.
Diagnostic chest CT with or without contrast; PET/CT may be considered when there is a solid nodule or solid component >=8 mm; tissue sampling and/or referral for further clinical evaluation. Management depends on comorbidities, patient preference, and probability of malignancy. Slowly growing nodules may be PET-negative, so biopsy or surgical evaluation may be more appropriate when feasible.Published estimated population prevalence 2% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 4B row
4X
Very suspicious with additional features
Category 3 or 4 nodules that carry additional features or imaging findings increasing suspicion for lung cancer (e.g., spiculation, lymphadenopathy, frank metastatic disease, a ground-glass nodule that doubles in size within a year).
Referral for further clinical evaluation (managed as a very-suspicious finding).Published estimated population prevalence under 1% (this is a prevalence figure, not a probability of malignancy).
Lung-RADS v2022 assessment categories table, Category 4X row
S
Significant non-lung-cancer finding modifier
Optional exam modifier added to a numeric Lung-RADS category 0-4 when there is a clinically significant or potentially clinically significant finding unrelated to lung cancer. Do not keep applying S to a finding that is already known and has been or is being evaluated unless there is an unexpected concerning change.
Manage according to the specific non-lung-cancer finding, using applicable ACR Incidental Findings recommendations or another appropriate clinical pathway; S does not alter the numeric Lung-RADS nodule category.Not a lung-cancer risk category. S flags a separate significant or potentially significant incidental finding.
Lung-RADS v2022 Note 15 (Exam Modifier) and v2022 Summary of Changes, section II.B (S Modifier)

Referências cruzadas

fronteira compartilhadaBI-RADS. Breast Imaging Reporting and Data System, 5th editionShares the ACR Reporting and Data System framework that BI-RADS established.
fronteira compartilhadaFleischner. Fleischner Society 2017 pulmonary nodule guidelinesBoth address pulmonary nodules on CT. Lung-RADS governs screening, Fleischner governs incidental nodules.

Histórico de versões

DataEventoDetalheSituação
2022-11-01revisedLung-RADS v2022 released, updating v1.1 (2019). evidênciaconfirmado
Quickstart da APIGET /api/v1/systems/lung-rads-2022aberto
curl -s "https://radcommons.laudos.ai/api/v1/systems/lung-rads-2022"
Ver documentação completa